§ 520.44

- (b) Conditions of use. It is used in dogs and cats as follows:
- (1) *Indications for use*. It is used in dogs and cats as a tranquilizer.
- (2) Amount. Dogs: 0.25 to 1.0 milligram per pound of body weight; Cats: 0.5 to 1.0 milligram per pound of body weight.
- (3) *Limitations*. The drug is administered orally. Dosage may be repeated as required. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
- (c) Conditions of use. It is used in dogs as follows:
- (1) *Indications for use*. It is used in dogs as an aid in tranquilization and as a preanesthetic agent.
- (2) Amount. Dogs: 0.25 to 1.0 milligram per pound of body weight.
- (3) Limitations. The drug is administered orally. Dosage may be repeated as required. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[46 FR 44443, Sept. 4, 1981, as amended at 49 FR 49091, Dec. 18, 1984; 52 FR 666, Jan. 8, 1987; 53 FR 40727, Oct. 18, 1988; 56 FR 37473, Aug. 7, 1991; 62 FR 35075, June 30, 1997]

§ 520.44 Acetazolamide sodium soluble powder.

- (a) Specifications. The drug is in a powder form containing acetazolamide sodium, USP equivalent to 25 percent acetazolamide activity.
- (b) Sponsor. See No. 010042 in \$510.600(c) of this chapter.
- (c) Conditions of use. (1) It is used in dogs as an aid in the treatment of mild congestive heart failure and for rapid reduction of intraocular pressure.¹
- (2) It is administered orally at a dosage level of 5 to 15 milligrams per pound of body weight daily.¹
- (3) For use only by or on the order of a licensed veterinarian. 1

§ 520.45 Albendazole oral dosage forms.

§ 520.45a Albendazole suspension.

- (a)(1) *Specifications*. The product contains 11.36 percent albendazole.
- (2) *Sponsor*. See No. 000069 in §510.600 of this chapter.
- (3) Related tolerances. See §556.34 of this chapter.
- (4) Conditions of use in cattle—(i) Amount. 4.54 milligrams per pound of body weight (10 milligrams per kilogram).
- (ii) Indications for use. For removal and control of the following internal parasites of cattle: Adult liver flukes (Fasciola hepatica); heads and segments of tapeworms (Moniezia benedeni, M. expansa); adult and 4th stage larvae of stomach worms (brown stomach worms including 4th stage inhibited larvae (Ostertagia ostertagi), barberpole worm (Haemonchus contortus, H. placei), small stomach worm (Trichostrongylus axei)); adult and 4th stage larvae of intestinal worms (thread-necked intestinal worm (Nematodirus spathiger, N. helvetianus), intestinal small worm (Cooperia punctata and C. oncophora)); adult stages of intestinal worms (hookworm (Bunostomum phlebotomum), bankrupt worm (Trichostrongylus colubriformis), nodular (Oesophagostomum worm radiatum)); adult and 4th stage larvae of lungworms (Dictyocaulus viviparus).
- (iii) Limitations. Administer as a single oral dose using dosing gun or dosing syringe. Do not slaughter within 27 days of last treatment. Do not use in female dairy cattle of breeding age: Do not administer to female cattle during first 45 days of pregnancy or for 45 days after removal of bulls. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
- (b)(1) *Specifications*. The product contains 4.55 or 11.36 percent albendazole.
- (2) Sponsor. See No. 000069 in \$510.600(c) of this chapter.
- (3) Related tolerances. See §556.34 of this chapter.
- (4) Conditions of use in sheep—(i) Amount. 7.5 milligrams per kilogram of body weight (3.4 milligrams per pound).

¹These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information